Physician profile
Joseph A Lash
NPI 1023040680
$16,442.70
in general payments reported to CMS, 2019-2025
19 companies · $3,785 in 2025
The $3,785 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $2,314 · 2021: $1,168 · 2022: $5,026 · 2023: $1,008 · 2024: $2,596 · 2025: $3,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Consulting Fee: $2,400 · Travel and Lodging: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.60 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,609.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $5,291.69 | 2020-2025 | Ffrct |
| Medtronic, INC. | $5,123.78 | 2021-2024 | Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $2,211.98 | 2019-2020 | |
| Inari Medical, INC. | $704.90 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $634.61 | 2020-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $555.48 | 2022-2024 | Watchman Access System |
| Edwards Lifesciences Corporation | $502.53 | 2024-2025 | Evoque, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.18 | 2019-2021 | |
| Abiomed | $235.50 | 2022-2023 | Impella |
| Abbott Laboratories | $224.29 | 2021-2023 | Navitor |
| Atricure, INC. | $162.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $138.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $117.14 | 2019-2025 | |
| Pfizer INC. | $101.20 | 2020 | |
| Cvrx, INC. | $83.21 | 2024 | Barostim Neo System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $63.45 | 2020-2025 | Camzyos |
| Novo Nordisk INC | $32.27 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.